Connexion
E-mail
Mot de passe
Afficher le mot de passe
Retenir
Mot de passe oublié ?
Devenir membre gratuitement
Inscription
Inscription
Devenir membre
Inscription gratuite
Devenir client
Découvrez nos services
Paramètres
Paramètres
Cotations dynamiques 
OFFON

AVIDITY BIOSCIENCES, INC.

(RNA)
  Rapport
SynthèseCotationsGraphiquesActualitésNotationsAgendaSociétéFinancesConsensusRévisionsDérivésFondsCommunauté 
SynthèseToute l'actualitéReco analystesAutres languesCommuniquésPublications officiellesActualités du secteur
Actualités dans d'autres langues sur AVIDITY BIOSCIENCES, INC.
09/11Avidity Biosciences Reports Third Quarter 2021 Financial Results and Recent Highlights ..
09/11AVIDITY BIOSCIENCES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION ..
09/11Avidity Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Month..
09/11Avidity Biosciences Reports Third Quarter 2021 Financial Results and Recent Highlights
04/11Avidity Announces First Person Dosed with an Antibody Oligonucleotide Conjugate (AOC&tr..
04/11Avidity Biosciences, Inc. Announces First Person Dose with an Antibody Oligonucleotide ..
02/11Avidity Biosciences to Participate in Upcoming Investor Conferences
02/11Certain Options of Avidity Biosciences, Inc. are subject to a Lock-Up Agreement Ending ..
02/11Certain Common Stock of Avidity Biosciences, Inc. are subject to a Lock-Up Agreement En..
18/10AVIDITY BIOSCIENCES : Says FDA Grants its AOC 1001 Myotonic Dystrophy Type 1 Treatment Fas..
18/10AVIDITY BIOSCIENCES : FDA Grants Fast Track Designation to AOC 1001 for the Treatment of M..
18/10Avidity Biosciences Lead Program Gets FDA Fast-Track Designation
01/09Health Care Stocks Reverse Losses as Biotechs Rise
01/09Top Midday Decliners
01/09Health Care Stocks Edging Lower, Biotechs Working to Limit Declines
01/09AVIDITY BIOSCIENCES : Shares Slide After Chief Medical Officer Steps Down
01/09AVIDITY BIOSCIENCES, INC. : Change in Directors or Principal Officers (form 8-K)
01/09Avidity Biosciences, Inc. Announces Executive Changes
31/08AVIDITY BIOSCIENCES : to Participate in Upcoming Investor Conferences
25/08AVIDITY BIOSCIENCES, INC. : Change in Directors or Principal Officers (form 8-K)
25/08AVIDITY BIOSCIENCES : Announces Changes to its Board of Directors
25/08Avidity Biosciences, Inc. Announces Board Changes
24/08AVIDITY BIOSCIENCES' : Myotonic Dystrophy Treatment Candidate Gets Orphan Designation in E..
24/08AVIDITY BIOSCIENCES : European Medicines Agency (EMA) Grants Orphan Designation for AOC 10..
16/08AVIDITY BIOSCIENCES : Enters Into Collaboration with FSHD Clinical Trial Network to Suppor..
16/08Avidity Biosciences, Inc. Enters into Collaboration with FSHD Clinical Trial Network to..
09/08AVIDITY BIOSCIENCES : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESU..
09/08Avidity Biosciences, Inc. Reports Earnings Results for the Second Quarter Ended June 30..
09/08AVIDITY BIOSCIENCES : Reports Second Quarter 2021 Financial Results and Recent Highlights
04/08AVIDITY BIOSCIENCES : Announces Proposed Public Offering of Common Stock (Form 8-K)
04/08AVIDITY BIOSCIENCES, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
04/08Avidity Biosciences, Inc. Entered into an Underwriting Agreement
04/08AVIDITY BIOSCIENCES : Prices Stock Offering at $18 Per Share
04/08AVIDITY BIOSCIENCES, INC. : Announces Pricing of Public Offering of Common Stock
03/08AVIDITY BIOSCIENCES : Results of Operations and Financial Condition (Form 8-K)
03/08AVIDITY BIOSCIENCES : to Launch $100 Million Common Stock Offering
02/08AVIDITY BIOSCIENCES, INC. : Results of Operations and Financial Condition (form 8-K)
02/08Avidity Biosciences Aims to Sell $100 Million in Shares to Fund AOC 1001 Trial
02/08AVIDITY BIOSCIENCES, INC. : Announces Proposed Public Offering of Common Stock
02/08AVIDITY BIOSCIENCES : Receives FDA Clearance for Early Stage Trial of Myotonic Dystrophy T..
02/08AVIDITY BIOSCIENCES : August 2021 Corporate Presentation
02/08AVIDITY BIOSCIENCES, INC. : Regulation FD Disclosure, Other Events, Financial Statements a..
02/08AVIDITY BIOSCIENCES : Receives IND Clearance from FDA to Proceed with the Phase 1/2 MARINA..
02/08Avidity Biosciences Receives IND Clearance from FDA to Proceed with the Phase 1/2 MARIN..
06/07AVIDITY BIOSCIENCES : Files for Potential Follow-On, Secondary Offerings
02/07AVIDITY BIOSCIENCES : SALES AGREEMENT (Form 8-K)
02/07AVIDITY BIOSCIENCES, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
25/06AVIDITY BIOSCIENCES, INC.(NASDAQGM : RNA) added to Russell Microcap Index
25/06AVIDITY BIOSCIENCES, INC.(NASDAQGM : RNA) added to Russell 3000E Growth Index
25/06AVIDITY BIOSCIENCES, INC.(NASDAQGM : RNA) added to Russell 3000E Index
25/06AVIDITY BIOSCIENCES, INC.(NASDAQGM : RNA) added to Russell Microcap Growth Index
25/06AVIDITY BIOSCIENCES, INC.(NASDAQGM : RNA) added to Russell Microcap Value Index
25/06AVIDITY BIOSCIENCES, INC.(NASDAQGM : RNA) added to Russell 3000E Value Index
17/06AVIDITY BIOSCIENCES, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
03/06AVIDITY BIOSCIENCES : June 2021 Corporate Presentation
19/05AVIDITY BIOSCIENCES, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (f..
19/05AVIDITY BIOSCIENCES : Announces Updates on the Pipeline and Platform at Virtual Investor a..
14/05AVIDITY BIOSCIENCES : Reports First Quarter 2021 Financial Results and Recent Highlights (..
14/05AVIDITY BIOSCIENCES : May Corporate Presentation
12/05AVIDITY BIOSCIENCES : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESU..
12/05Avidity Biosciences, Inc. Reports Unaudited Financial Results for the First Quarter End..
03/05AVIDITY BIOSCIENCES : to Host Virtual Investor and Analyst Event on May 19, 2021
14/04AVIDITY BIOSCIENCES : April Corporate Presentation
29/03AVIDITY BIOSCIENCES : March Corporate Presentation
25/03AVIDITY BIOSCIENCES : to Participate in Upcoming Investor Conferences
15/03AVIDITY BIOSCIENCES : Narrows Q4 Loss/Share, Ups Collaboration Revenue
15/03AVIDITY BIOSCIENCES : Management's Discussion and Analysis of Financial Condition and Resu..
15/03Avidity Biosciences, Inc. Reports Unaudited Consolidated Earnings Results for the Fourt..
15/03AVIDITY BIOSCIENCES : Reports Fourth Quarter and Year-End 2020 Financial Results and Recen..
24/02AVIDITY BIOSCIENCES : February Corporate Presentation
17/02AVIDITY BIOSCIENCES : to Present at the 10th Annual SVB Leerink Global Healthcare Conferen..
22/01AVIDITY BIOSCIENCES : Names Chief Technical Officer
21/01AVIDITY BIOSCIENCES, INC. : Change in Directors or Principal Officers (form 8-K)
21/01Avidity Biosciences Appoints W. Michael Flanagan as Chief Technical Officer
11/01AVIDITY BIOSCIENCES, INC. : Change in Directors or Principal Officers (form 8-K)
1  2Suiv.
Prochain événement sur AVIDITY BIOSCIENCES, INC.